Envisia Therapeutics Debuts with $25 Million Series A Financing
Transformative New Ophthalmology Company Licenses Technology from Liquidia
RESEARCH TRIANGLE PARK, NC– November 12, 2013 – Envisia Therapeutics, a new biotechnology company formed by Liquidia Technologies, today announced the Company’s debut, which is being backed by $25 million in Series A financing. Envisia will focus on addressing unmet medical needs in various areas of ophthalmology. Envisia’s lead product, ENV515, is an extended-release formulation of a prostaglandin analogue. ENV515 has the potential to offer glaucoma patients an innovative product that can provide a sustained reduction in intraocular pressure (IOP) over many months after single administration.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.